-
NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension
•
The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular pulmonary artery radiofrequency ablation catheter, marking it as a novel product in the medical device landscape. This innovative catheter employs a puncture intervention technique to access the bloodstream, targeting pulmonary arterial hypertension by disrupting the…
-
Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors
•
Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration and supply agreement with Xuanzhu Biopharma to explore the combination therapy of Tyvyt (sintilimab) with KM-501, a novel HER-2 bispecific antibody drug conjugate (ADC). This partnership aims to develop potential treatment options for advanced solid…
-
Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy
•
Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its fixed-dose combination tablets of rosuvastatin and ezetimibe. This therapy is indicated for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). This product marks the first…
-
Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment
•
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its acquisition of development, manufacturing, and commercialization rights for the gene therapy botaretigene sparoparvovec from MeiraGTx Holdings (NASDAQ: MGTX) for the treatment of X-linked retinitis pigmentosa (XLRP). Janssen will pay an upfront fee of USD 65…
-
AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua
•
AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for its ligand-conjugated antisense oligonucleotide (LICA) Wainua (eplontersen) as a treatment for hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN/ATTRv-PN) in adults. Developed in collaboration with Ionis Pharmaceuticals (NASDAQ: IONS),…
-
Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research
•
China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma Inc. (TYO: 4503), focusing on Elpiscience’s innovative bi-specific macrophage engager, ES019, along with another program. The partnership will involve joint early-stage research on these two initiatives, with Elpiscience granting Astellas the option to include up…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology
•
XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly RMB 100 million (USD 14 million) in a Series A financing round. The round was led by Legend Capital, with participation from existing investors TIgerYeah Capital, Proxima Ventures, Dalton Venture, and Tao Capital. The funds…
